Have a Little Fun!

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

Risk not higher compared with ZDV-3TC-LPV/r or TDF-FTC-ATV/r in HIV-infected women in the U.S.

HealthDay News — For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) or TDF-FTC with ritonavir-boosted atazanavir (ATV/r), according to a study published in the April 26 issue of the New England Journal of Medicine.

Kathryn Rough, ScD, from Harvard Medical School in Boston, and colleagues compared the risks of adverse birth outcomes among infants with in utero exposure to the 3 regimens, using data from two U.S.-based cohort studies.